Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00286312
Status:
COMPLETED
Last Update Posted:
2008-05-21
First Post:
2006-02-02
Brief Title:
Myocardial Infarction Size Reduction With Atorvastatin
Sponsor:
RD Cardiologie
Organization:
RD Cardiologie
Study Overview
Official Title:
Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy The REPERATOR Study
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if oral atorvastatin administered just before percutaneous coronary angioplasty for acute myocardial infarction improves early and late heart function as compared to placebo
Detailed Description:
Left ventricular remodelling after a myocardial infarction refers to changes in shape and function of the infarcted and uninfarcted myocardium Remodelling begins minutes after acute myocardial infarction and may continue for months or years leading to dilation of the left ventricle LV and an increased LV volume As studies show LV volume strongly correlates with long-term mortality Reperfusion after a period of ischaemia through medication or PTCA leads to so-called reperfusion injury This results in myocardial dysfunction and damage which can lead to LV remodelling
In a study where atorvastatin was administered at the onset of reperfusion infarct size was reduced Atorvastatin led to protection of the reperfused myocardium independently of its effects on cholesterol
The objective is to measure the effect of atorvastatin administered orally before reperfusion therapy by PTCA on infarct size and microvascular reperfusion
In a study where atorvastatin was administered at the onset of reperfusion infarct size was reduced Atorvastatin led to protection of the reperfused myocardium independently of its effects on cholesterol
The objective is to measure the effect of atorvastatin administered orally before reperfusion therapy by PTCA on infarct size and microvascular reperfusion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None